Ahead of election years, the cost and future of health care has become one of the top debates for better than two decades now. Most politicians say that they want to lower…
Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
Here's a look at the five best- and five worst-performing stocks among the Dow Jones industrial average this past year.
The December 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Microsoft, Pfizer and Intel above all other Dow stocks.
Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to watch for going into 2020.
One theme that investors love in good times and in bad is dividend investing. One strategy that has been around for years is known as the Dogs of the Dow.
The November 29 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
As of the most recently reported period, short sellers favored Apple, Microsoft and Intel above all other Dow stocks.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as early 2020, if only a few things come to fruition. There does…
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
As of the most recently reported settlement date, short sellers still favored Microsoft, Intel and Pfizer above all other Dow stocks.
With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the Dow are still holding the index back from even stronger gains.
Shares of Merck and Pfizer both got boosts after they reported their most recent quarterly results before the opening bell Tuesday.
